At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 2, 2026 at 08:32 ET
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up.
- 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
- 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
- Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
- 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access